Review of bile acid homeostasis regulation in liver disease and cancer

This publication is a narrative review rather than a systematic review or meta-analysis. Its scope encompasses the regulation of bile acids homeostasis within a broad range of liver diseases, specifically cholestasis, hepatic fibrosis, cirrhosis, hepatocellular carcinoma, MASLD, and MASH. The text does not provide a defined study population, sample size, or specific intervention details, as these fields are not reported in the source material.

The authors discuss the physiological context of bile acid regulation as it pertains to these conditions. No pooled effect sizes, p-values, or confidence intervals are presented because this is not a quantitative synthesis of primary trials. The review focuses on the conceptual framework of bile acid management in liver pathology rather than reporting specific clinical trial results.

Significant limitations are inherent to the lack of reported data. The source does not detail primary or secondary outcomes, follow-up periods, or specific adverse events. Consequently, the practice relevance and certainty of any conclusions regarding clinical management are not explicitly defined by the authors in this text. Readers should interpret this review as a qualitative overview of a biological mechanism rather than a guide for specific therapeutic decisions.